Autoinflammatory & rare systemic diseases
Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS)
Authors' conclusion
In summary, the benefit risk ratio of maternal and paternal anti-IL-1 exposure during conception and pregnancy in our CAPS patients was favourable.
Study context
- Population
- Consecutive adult CAPS patients and their partners, single centre, January 2012–July 2024; teratogenic co-therapies excluded
- Participants
- 112 patients11 pregnancies
- Exposure
- Maternal vs paternal anti-IL-1 exposure before conception and/or during pregnancy
- Maternal exposuren = 8
- Paternal exposuren = 3
- Outcome
- Pregnancy and neonatal outcomes after anti-IL-1 exposure
Methodological detailsconsecutive patients
- Consecutive patients
Main finding
As reported in the abstract
Pregnancy and neonatal outcomes
- Miscarriage
- 1
- Preterm birth
- 1
- Gestational age, mean
- 37 + 6 weeks
- Birth weight, average
- 3028 g
- Congenital malformations
- 0
Observational data: associations, not effects.
Further findings
CAPS in offspring
- CAPS diagnosed in offspring
- 5 of 11
- Hearing loss or amyloidosis in affected offspring
- 0
- All achieved effective disease control early
Treatment during maternal exposures
- Switched to anakinra
- 6
- Refused switch, continued canakinumab
- 1
- Switched back to canakinumab due to significant local injection reactions
- 1
- All patients received canakinumab at conception
Safety
Neonatal complications
- Presumed sepsis (culture negative) requiring IV antibiotics
- 1
- Mild respiratory syncytial virus infection
- 1
Original publication
Pregnancy outcomes after maternal and paternal anti-IL-1 treatment exposure in cryopyrin-associated periodic syndromes (CAPS). Rheumatology (Oxford). Published 24 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →